Cargando…

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines

Virus-like particles (VLP) spontaneously assemble from viral structural proteins. They are naturally biocompatible and non-infectious. VLP can serve as a platform for many potential vaccine epitopes, display them in a dense repeating array, and elicit antibodies against non-immunogenic substances, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caldeira, Jerri C., Perrine, Michael, Pericle, Federica, Cavallo, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291217/ https://www.ncbi.nlm.nih.gov/pubmed/32349216 http://dx.doi.org/10.3390/v12050488

Ejemplares similares

Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform
por: Caldeira, Jerri, et al.
Publicado: (2015)

Stability and assembly in vitro of bacteriophage PP7 virus-like particles
por: Caldeira, Jerri C, et al.
Publicado: (2007)

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
por: Rolih, Valeria, et al.
Publicado: (2020)

Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign Peptides
por: Caldeira, Jerri C, et al.
Publicado: (2011)

Display of single-chain variable fragments on bacteriophage MS2 virus-like particles
por: Lino, Christopher A., et al.
Publicado: (2017)

Virus-like Particle Vaccines and Platforms for Vaccine Development
por: Kheirvari, Milad, et al.
Publicado: (2023)

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
por: Bolli, Elisabetta, et al.
Publicado: (2017)

Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development
por: Zhao, Yiwen, et al.
Publicado: (2022)

Virus like particles as a platform for cancer vaccine development
por: Ong, Hui Kian, et al.
Publicado: (2017)

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
por: Srivastava, Vartika, et al.
Publicado: (2023)

Inclusion of cGAMP within virus‐like particle vaccines enhances their immunogenicity
por: Chauveau, Lise, et al.
Publicado: (2021)

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers
por: Nooraei, Saghi, et al.
Publicado: (2021)

Virus-Like Particles, a Versatile Subunit Vaccine Platform
por: Donaldson, Braeden, et al.
Publicado: (2014)

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
por: Collins, Katharine A., et al.
Publicado: (2017)

Hepatitis B core-based virus-like particles: A platform for vaccine development in plants
por: Moradi Vahdat, Maryam, et al.
Publicado: (2021)

Virus‐like particles for vaccination against cancer
por: Mohsen, Mona O., et al.
Publicado: (2019)

Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine
por: Chen, Wei, et al.
Publicado: (2020)

Platforms, advances, and technical challenges in virus-like particles-based vaccines
por: Gupta, Reeshu, et al.
Publicado: (2023)

Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine
por: Zhang, XiZhen, et al.
Publicado: (2011)

Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
por: Tornesello, Anna Lucia, et al.
Publicado: (2022)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
por: Tortellini, Eeva, et al.
Publicado: (2023)

Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig
por: Jeoung, Hye-Young, et al.
Publicado: (2011)

Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review
por: Wang, Yang, et al.
Publicado: (2023)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
por: Ho, Joan Kha-Tu, et al.
Publicado: (2020)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Inhibition of JAK3 with a novel, selective, and orally active small molecule induces therapeutic response in T-cell malignancies
por: Ross, Jeremy A., et al.
Publicado: (2013)

Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity
por: Chan, Jo-Anne, et al.
Publicado: (2019)

Virus-Like Particles as an Instrument of Vaccine Production
por: Syomin, B. V., et al.
Publicado: (2019)

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development
por: Kushnir, Natasha, et al.
Publicado: (2012)

Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine
por: Dennis, Susan J., et al.
Publicado: (2017)

Dose immunogenicity study of a plant-produced influenza virus-like particle vaccine in layer hens
por: Abolnik, Celia, et al.
Publicado: (2022)

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
por: Tariq, Hasnat, et al.
Publicado: (2022)

Modular vaccine platform based on the norovirus-like particle
por: Lampinen, Vili, et al.
Publicado: (2021)

Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus
por: Urakami, Akane, et al.
Publicado: (2017)

Construction and Immunogenicity of Virus-Like Particles of Feline Parvovirus from the Tiger
por: Jiao, Cuicui, et al.
Publicado: (2020)

Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells
por: Tsai, Shan-Ko, et al.
Publicado: (2022)

A novel delivery platform based on Bacteriophage MS2 virus-like particles
por: Fu, Yu, et al.
Publicado: (2016)

104 Immunogenicity and Safety Aspects of Adeno-Associated Virus–Like Particles (AAVLPS) as Carriers for B-Cell Vaccines
por: Jensen-Jarolim, Erika, et al.
Publicado: (2012)

A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
por: Mohsen, Mona O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o6iefnis2ilavdilga3f550ahp